LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.

Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Mar 2018Cited by 11 (Europe PMC)

PMID29547049DOI10.4158/ep172000.orPepBankPUB-29547049

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In NET patients with prior octreotide, lanreotide had a nonsignificantly lower percentage of rescue days versus placebo (difference -6.9, P=.4332).
In plain wordsRescue octreotide days did not differ significantly between lanreotide and placebo in patients with prior octreotide.
Peptide
Lanreotide
Outcome
No significant changeRescue octreotide days after prior octreotide
Study
n = 64
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
120 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
LS mean difference in percentage of days with SC octreotide rescue
−6.9%
prior octreotide group, lanreotide vs placebo
Source sentences
Summary
Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares [LS] mean difference -19.1, P = .0477 and -6.9, P = .4332, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks.
Summary · context
Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide.
Report a problemFND-2954704902
02HumanRandomized controlled trialEfficacy outcome
In treatment-naive NET patients, lanreotide reduced rescue octreotide days versus placebo (LS mean difference -19.1, P=.0477).
In plain wordsLanreotide reduced rescue octreotide days compared with placebo in treatment-naive patients.
Peptide
Lanreotide
Outcome
DecreaseRescue octreotide days in treatment-naive patients
Study
n = 51
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
120 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
LS mean difference in percentage of days with SC octreotide rescue
−19.1%
de novo group, lanreotide vs placebo
Source sentences
Summary
Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares [LS] mean difference -19.1, P = .0477 and -6.9, P = .4332, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks.
Summary · context
Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide.
Report a problemFND-2954704901
03HumanRandomized controlled trialEfficacy outcome
In NET patients with prior octreotide, symptom days were nonsignificantly lower with lanreotide versus placebo (difference -10.9, P=.0746).
In plain wordsModerate or severe symptom days did not differ significantly between lanreotide and placebo after prior octreotide.
Peptide
Lanreotide
Outcome
No significant changeModerate/severe symptom days after prior octreotide
Study
n = 64
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
120 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
LS mean difference in percentage of days with moderate/severe diarrhea and/or flushing
−10.9%
prior octreotide group, lanreotide vs placebo
Source sentences
Summary
The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference -14.6, P = .0140 and -10.9, P = .0746, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks.
Summary · context
Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide.
Report a problemFND-2954704904
04HumanRandomized controlled trialEfficacy outcome
In treatment-naive NET patients, lanreotide reduced moderate/severe diarrhea and/or flushing days versus placebo (difference -14.6, P=.0140).
In plain wordsLanreotide reduced moderate or severe symptom days compared with placebo in treatment-naive patients.
Peptide
Lanreotide
Outcome
DecreaseModerate/severe symptom days in treatment-naive patients
Study
n = 51
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
120 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
LS mean difference in percentage of days with moderate/severe diarrhea and/or flushing
−14.6%
de novo group, lanreotide vs placebo
Source sentences
Summary
The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference -14.6, P = .0140 and -10.9, P = .0746, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks.
Summary · context
Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide.
Report a problemFND-2954704903
05HumanNon-randomized trialSafety outcome
In NET patients, transition from octreotide to lanreotide was generally well tolerated.
In plain wordsPatients generally tolerated the transition from octreotide to lanreotide.
Peptide
Lanreotide
Outcome
Not applicableTolerability of transition
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
120 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
The transition from octreotide to lanreotide was generally well-tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks.
Summary · context
Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide.
Report a problemFND-2954704905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.